China SFDA To Step Up Actions Against Counterfeit Of 'Essential Drugs'
This article was originally published in PharmAsia News
China's State FDA plans to increase its operations with law-enforcement agencies to stop the market of counterfeit drugs, beginning with medicines on its list of those deemed essential.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.